Abstract
To determine the cost effectiveness of vaccinating against Lyme disease, we used a decision tree to examine the impact on society of six key components. The main measure of outcome was the cost per case averted. Assuming a 0.80 probability of diagnosing and treating early Lyme disease, a 0.005 probability of contracting Lyme disease, and a vaccination cost of $50 per year, the mean cost of vaccination per case averted was $4,466. When we increased the probability of contracting Lyme disease to 0.03 and the cost of vaccination to $100 per year, the mean net savings per case averted was $3,377. Since few communities have average annual incidences of Lyme disease >0. 005, economic benefits will be greatest when vaccination is used on the basis of individual risk, specifically, in persons whose probability of contracting Lyme disease is >0.01.
Full Text
The Full Text of this article is available as a PDF (109.7 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cartter M. L., Mshar P., Hadler J. L. The epidemiology of Lyme disease in Connecticut. Conn Med. 1989 Jun;53(6):320–323. [PubMed] [Google Scholar]
- Centers for Disease Control and Prevention (CDC) Lyme disease -- United States, 1996. MMWR Morb Mortal Wkly Rep. 1997 Jun 13;46(23):531–535. [PubMed] [Google Scholar]
- Centers for Disease Control and Prevention (CDC) Lyme disease -- United States, 1996. MMWR Morb Mortal Wkly Rep. 1997 Jun 13;46(23):531–535. [PubMed] [Google Scholar]
- Coyle B. S., Strickland G. T., Liang Y. Y., Peña C., McCarter R., Israel E. The public health impact of Lyme disease in Maryland. J Infect Dis. 1996 May;173(5):1260–1262. doi: 10.1093/infdis/173.5.1260. [DOI] [PubMed] [Google Scholar]
- Fix A. D., Strickland G. T., Grant J. Tick bites and Lyme disease in an endemic setting: problematic use of serologic testing and prophylactic antibiotic therapy. JAMA. 1998 Jan 21;279(3):206–210. doi: 10.1001/jama.279.3.206. [DOI] [PubMed] [Google Scholar]
- Keller D., Koster F. T., Marks D. H., Hosbach P., Erdile L. F., Mays J. P. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA. 1994 Jun 8;271(22):1764–1768. [PubMed] [Google Scholar]
- Luger S. W., Paparone P., Wormser G. P., Nadelman R. B., Grunwaldt E., Gomez G., Wisniewski M., Collins J. J. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother. 1995 Mar;39(3):661–667. doi: 10.1128/AAC.39.3.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Maes E., Lecomte P., Ray N. A cost-of-illness study of Lyme disease in the United States. Clin Ther. 1998 Sep-Oct;20(5):993–992. doi: 10.1016/s0149-2918(98)80081-7. [DOI] [PubMed] [Google Scholar]
- Massarotti E. M., Luger S. W., Rahn D. W., Messner R. P., Wong J. B., Johnson R. C., Steere A. C. Treatment of early Lyme disease. Am J Med. 1992 Apr;92(4):396–403. doi: 10.1016/0002-9343(92)90270-l. [DOI] [PubMed] [Google Scholar]
- Padilla M. L., Callister S. M., Schell R. F., Bryant G. L., Jobe D. A., Lovrich S. D., DuChateau B. K., Jensen J. R. Characterization of the protective borreliacidal antibody response in humans and hamsters after vaccination with a Borrelia burgdorferi outer surface protein A vaccine. J Infect Dis. 1996 Oct;174(4):739–746. doi: 10.1093/infdis/174.4.739. [DOI] [PubMed] [Google Scholar]
- Schoen R. T., Meurice F., Brunet C. M., Cretella S., Krause D. S., Craft J. E., Fikrig E. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. J Infect Dis. 1995 Nov;172(5):1324–1329. doi: 10.1093/infdis/172.5.1324. [DOI] [PubMed] [Google Scholar]
- White D. J., Chang H. G., Benach J. L., Bosler E. M., Meldrum S. C., Means R. G., Debbie J. G., Birkhead G. S., Morse D. L. The geographic spread and temporal increase of the Lyme disease epidemic. JAMA. 1991 Sep 4;266(9):1230–1236. [PubMed] [Google Scholar]